Correlation of ultrasonographic and mammographic characteristics with expressions of ER, PR, HER-2 in breast ductal carcinoma in situ

doi:10.3877/cma. j. issn.1674-0807.2014.06.005

Abstract

Abstract:

Objective

To explore the relationship of ultrasonographic and mammographic characteristics with expressions of ER,PR and HER-2 in breast ductal carcinoma in situ (DCIS).

Methods

The clinical, pathological, ultrasonographic and mammographic data of 49 cases of DCIS in the First Affiliated Hospital of Shihezi University from January 2010 to March 2014 were retrospectively analyzed. χ² test was used to detect the correlation of age, ultrasonographic and mammographic characteristics with the expressions of ER,PR and HER-2. Fisher’s exact test was used to detect the correlation between the diameter of mass and the expression of ER, PR and HER-2.

Results

The positive rate of ER, PR and HER-2 was 81.25% (26/32),87.50% (28/32) and 68.76% (22/32) in DCIS group with mass ultrasonographic characteristics, 8/17,8/17 and 10/17 in DCIS group with non-mass ultrasonographic characteristics. The positive rates of ER and PR in mass group were significantly higher than those in non-mass group (χ²=6.110,7.356;P=0.013,0.007),while HER-2 positive rate showed no significant difference between two groups (χ²=0.483, P=0.487). The positive rate of ER, PR and HER-2 was 60.61% (20/33), 75.76% (25/33) and 75.76% (25/33) in mammographic calcification group of DCIS,14/16,11/16 and 7/16 in mammographic non-calcification group.HER-2 positive rate in mammographic calcification group was significantly higher than that in mammographic non-calcification group (χ²=4.872,P=0.027), while there were no statistical differences in positive rates of ER and PR between two groups (χ² = 2.512, 0.031;P = 0.113,0.860). There were 18 patients with calcification found by ultrasound, accounting for 54.54% of the patients with calcification found by mammography (33 cases).

Conclusion

ER and PR are highly expressed in DCIS with mass ultrasonographic characteristics, and HER-2 is highly expressed in DCIS with mammographic calcification characteristics, which may provide guidance for the individualized diagnosis and treatment in clinic.

Key words: Ductal carcinoma in situ, Ultrasonography, Radiography, Receptors, estrogen;Receptors, progesterone, Genes, erbB-2

Meiqin Yuan, Kunxia Guo, Kuican Liu, Jing Cheng, Yan Chang. Correlation of ultrasonographic and mammographic characteristics with expressions of ER, PR, HER-2 in breast ductal carcinoma in situ[J]. Chinese Journal of Breast Disease(Electronic Edition), 2014, 08(06): 402-407.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma. j. issn.1674-0807.2014.06.005

https://zhrxbzz.cma-cmc.com.cn/EN/Y2014/V08/I06/402

Figures/Tables 8

References 18

[1]	Lakhani SR, Ellis IO, Schnitt SJ, et al. WHO classification of tumors of the breast[M].4th ed.Lyon: IARC Press,2012.
[2]	Kerlikowske K. Epidemiology of ductal carcinoma in situ[J]. J Natl Cancer Inst Monogr,2010,2010(41):139-141.
[3]	牛昀.乳腺导管内癌的基础与临床研究: 一个应倍加重视的领域[J/CD]. 中华乳腺病杂志: 电子版,2008,2(6):626-633.
[4]	Kasami M, Uematsu T, Honda M, et al. Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre-and post-neoadjuvant chemotherapy [J].Breast,2008,17(5):523-527.
[5]	Kim SH, Seo BK, Lee J, et al. Correlation of ultrasound findings with histology, tumor grade, and biological markers in breast cancer[J]. Acta Oncol,2008,47(8):1531-1538.
[6]	曾红艳,曹永政,彭格红,等.乳腺癌超声征象与ER、PR、C-erbB-2 表达的相关性研究[J]. 中国医学影像技术,2007,23(12):1827-1820.
[7]	美国放射学院. 乳腺影像报告与数据系统乳腺影像图谱[M].4 版. 李洁,译. 北京: 北京大学医学出版社, 2010:290-291.
[8]	American College of Radiology. Breast imaging reporting and data system: ACR BI-RADS-breast imaging atlas [M]. 4th ed. Reston: American College of Radiology,2003.
[9]	《乳腺癌HER2 检测指南(2009 版)》编写组.乳腺癌HER2检测指南(2009 版)[J]. 中华病理学杂志,2009,38(12):836-840.
[10]	朱庆莉,姜玉新,孙强,等. 乳腺癌超声征象与病理组织学类型及组织学分级的联系[J].中国超声影像学杂志,2005,14(9):674-677.
[11]	Hashimoto BE. Sonography of ductal carcinoma in situ [J].Ultrasound Clin,2006,1(4):631-643.
[12]	Soo MS, Baker JA, Rosen EL. Sonographic detection and sonographically guided biopsy of breast microcalcifications[J].Am J Roentgenol,2003,180(4):941-948.
[13]	Zhang W, Gao EL, Zhou YL, et al. Different distribution of breast ductal carcinoma in situ, ductal carcinoma in situ with microinvasion, and invasion breast cancer[J]. World J Surg Oncol,2012,10:262.
[14]	连臻强,张江宇,王颀.等.乳腺导管内癌及其微浸润癌病理和生物学指标表达差异的临床意义[J/CD].中华乳腺病杂志: 电子版,2011,5(4):419-425.
[15]	黄自明,赵倩倩,李杰. 乳腺癌组织中C-erbB-2,p53,ER 和PR 的表达及临床意义[J]. 中华实用诊断与治疗杂志,2011,25(7):636-637.
[16]	Rakovitch E, Nofech-Mozes S, Hanna W,et al. HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ[J]. Br J Cancer,2012,106(6):1160-1165.
[17]	Silverstein MJ, Lagios MD, Groshen S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast[J]. N Engl J Med,1999,340(19):1455-1461.
[18]	Brennan ME, Turner RM, Ciatto S, et al. Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer[J]. Radiology,2011,260(1):119-128.

腺体类型	局部不对称致密影(不伴/伴钙化)	结节(不伴/伴钙化)	单纯钙化	未见异常	合计
脂肪型	2(1/1)	4(1/3)	4	0	10
少量腺体型	0(0/0)	6(2/4)	6	1	13
多量腺体型	4(1/3)	1(0/1)	6	4	15
致密腺体型	1(1/0)	1(0/1)	4	5	11
合计	7(3/4)	12(3/9)	20	10	49

腺体类型	局部不对称致密影(不伴/伴钙化)	结节(不伴/伴钙化)	单纯钙化	未见异常	合计
脂肪型	2(1/1)	4(1/3)	4	0	10
少量腺体型	0(0/0)	6(2/4)	6	1	13
多量腺体型	4(1/3)	1(0/1)	6	4	15
致密腺体型	1(1/0)	1(0/1)	4	5	11
合计	7(3/4)	12(3/9)	20	10	49

因素	例数	ER(例)		χ²值	P值	PR(例)		χ²值	P值	HER-2(例)		χ²值	P值
因素	例数	-	+	χ²值	P值	-	+	χ²值	P值	-	+	χ²值	P值
年龄(岁)
≤50	31	7	24	2.563	0.109	8	23	0.023	0.880	11	20	0.023	0.879
＞50	18	8	10	2.563	0.109	5	13	0.023	0.880	6	12	0.023	0.879
超声表现
肿块型	32	6	26	6.110	0.013	4	28	7.356	0.007^a	10	22	0.483	0.487
非肿块型	17	9	8	6.110	0.013	9	8	7.356	0.007^a	7	10	0.483	0.487
X线摄影表现
钙化型	33	13	20	2.512	0.113^a	8	25	0.031	0.860^a	8	25	4.872	0.027
非钙化型	16	2	14	2.512	0.113^a	5	11	0.031	0.860^a	9	7	4.872	0.027

因素	例数	ER(例)		χ²值	P值	PR(例)		χ²值	P值	HER-2(例)		χ²值	P值
因素	例数	-	+	χ²值	P值	-	+	χ²值	P值	-	+	χ²值	P值
年龄(岁)
≤50	31	7	24	2.563	0.109	8	23	0.023	0.880	11	20	0.023	0.879
＞50	18	8	10	2.563	0.109	5	13	0.023	0.880	6	12	0.023	0.879
超声表现
肿块型	32	6	26	6.110	0.013	4	28	7.356	0.007^a	10	22	0.483	0.487
非肿块型	17	9	8	6.110	0.013	9	8	7.356	0.007^a	7	10	0.483	0.487
X线摄影表现
钙化型	33	13	20	2.512	0.113^a	8	25	0.031	0.860^a	8	25	4.872	0.027
非钙化型	16	2	14	2.512	0.113^a	5	11	0.031	0.860^a	9	7	4.872	0.027

肿块最大径	例数	ER(例)		P值	PR(例)		P值	HER-2(例)		P值
肿块最大径	例数	-	+	P值	-	+	P值	-	+	P值
≥2 cm	14	4	10	0.365^a	3	11	0.295^a	4	10	1.000^a
＜2 cm	18	2	16	0.365^a	1	17	0.295^a	6	12	1.000^a

Please choose a citation manager

Content to export